June 22, 2022
Article
Six are currently on the market and more are in the pipeline.
May 18, 2022
Across the globe, new drugs — injections, topical and oral — are being developed to help patients with atopic dermatitis.
May 16, 2022
Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%, there were also adverse events associated with high eosinophil levels in patients who had switched from a different biologic before starting Dupixent.
May 13, 2022
Xolair (omalizumab), Fasenra (benralizumab), Dupixent (dupilumab) and Nucala (mepolizumab) can now be self-administered.